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http://dx.doi.org/10.1016/j.jfma.201Background/purpose: Nocardia are ubiquitous in the environment worldwide and cause a va-
riety of infections. Clinical manifestations and outcomes of nocardiosis can vary with different
populations, host immunity, and presentations. The purpose of this study was to analyze the
differences in clinical characteristics, antimicrobial susceptibility, and outcomes for patients
with skin, lung, and disseminated nocardiosis.
Methods: We conducted a retrospective survey of culture-proven nocardial infections in 81
patients with invasive nocardiosis over an 18-year period at the National Taiwan University
Hospital. The clinical syndromes included skin infections (nZ 44), localized pulmonary infec-
tions (n Z 24), and disseminated infections (n Z 13).
Results: Disseminated nocardiosis included lung and brain involvement (7 patients), brain and
skin involvement (2 patients), localized brain abscess (1 patient), lung involvement with
bacteremia (1 patient), lymphadenitis (1 patient), and liver cirrhosis with spontaneous nocar-
dial peritonitis (1 patient). Eleven (14%) of all patients died due to nocardiosis. In comparison
with those with skin infections, patients with lung and disseminated nocardiosis tended to havehave no conflicts of interest relevant to this article.
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Patients with lung and disseminated nocardiosis 743chronic lung disease, malignancy, concomitant bacteremia, were often misdiagnosed as having
tuberculosis, were receiving immunosuppressive treatments, and demonstrated an increased
mortality. Nocardia strains isolated from patients with lung infections or disseminated infec-
tions tended to have lower in vitro antimicrobial susceptibility than those isolated from skin
infections [cefotaxime: 67% (lung) vs. 86% (skin); trimethoprim/sulfamethoxazole: 75%
(disseminated) vs. 97% (skin)].
Conclusion: These results highlight the protean disease manifestations and antimicrobial sus-
ceptibility of Nocardia and indicate the need to address the option of combined antimicrobial
therapy for lung and disseminated nocardiosis.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Nocardia is a genus of aerobic, Gram-positive, branching,
filamentous, weakly acid-fast bacteria. The organisms
contain mycolic acids in the cell wall, are closely related
to Mycobacterium, and are considered aerobic actino-
mycetes.1 Nocardia can be found in soil, rotten plants,
dust, or water and can infect humans via skin inoculation
or respiratory inhalation. There are 88 species of
Nocardia known at present, 46 of which have been
recorded as human pathogens.1 The most common spe-
cies are Nocardia asteroides and Nocardia brasiliensis.
Nocardia usually infect hosts with impaired cellular
immunity.
Nocardiosis is an acute or chronic suppurative disease.
The confounding factors associated with nocardiosis
include organ transplantation, human immunodeficiency
virus (HIV) infection, malignancy, and chronic lung dis-
ease.2e4 Coinfection with Aspergillus, cytomegalovirus, or
Mycobacterium have also been reported.5e7 Insidious
nocardial infections are often misdiagnosed as Actinomy-
cosis, Mycobacterium, Cryptococcus, or Toxoplasma in-
fections or as malignancies. Patient outcome is affected by
a delay in diagnosis,8 the presence of concomitant dis-
eases,5 the particular species of Nocardia,4 and inappro-
priate therapy.9
We reviewed the clinical characteristics, treatment,
antimicrobial susceptibility, and outcomes of patients with
nocardiosis at a university hospital in northern Taiwan. The
objective was to determine the differences in clinical
presentation, antimicrobial characteristics, and outcomes
among patients with lung and disseminated nocardiosis
compared to those with skin infections.Patients and methods
Study settings
The study was conducted at the National Taiwan University
Hospital (NTUH), a major teaching hospital in northern
Taiwan with a total capacity of 2500 beds. This hospital
offers primary and tertiary care for patients with acute
diseases. All culture-proven cases of nocardiosis diagnosed
at NTUH from January 1988 through December 2006 were
included and in-hospital outcomes as the end point by chart
review.Definition of nocardiosis
This was a retrospective analysis. According to chart re-
cords, the Nocardia isolates were obtained from various
clinical specimens, including pus from skin abscesses,
sputum, lung aspirate, pleural effusion, resected pleural
tumor, brain abscess, blood, and ascites. Nocardiosis was
considered a definite diagnosis when Nocardia was
repeatedly isolated or one isolate from sterile site. The
participants of this study were divided on the basis of
infection type into cutaneous, pulmonary only, and
disseminated cases. Histological culture of the bacteria on
bronchoalveolar lavage or lung aspiration was required for
diagnosis of pulmonary nocardiosis. Findings of infection in
the brain, two or more noncontiguous organs, or in the
blood were required for diagnosis of disseminated nocar-
diosis.10 Nocardiosis was defined as a cause of death if the
clinical condition deteriorated and the patients died.
Microbiological methods
Specimens of suspected Nocardia species were smeared
onto slides, Gram-stained to detect the presence of pre-
dominant Gram-positive filamentous organisms, acid-fast
stained using a modified method, and incubated for at
least 2 weeks on agar plates. Blood was cultured using the
BACTEC blood culture system (Becton, Dickinson, and
Company, Sparks, MD, USA). Identification of the isolates to
the species level was performed using conventional
biochemical tests for Nocardia, which involved hydrolysis of
casein, xanthine, hypoxanthine, and tyrosine.11 Antimi-
crobial susceptibility testing was performed using the disk
diffusion method with amikacin, minocycline, cefotaxime,
trimethoprimesulfamethoxazole (TMP/SMX), ampicillin,
gentamicin, or ciprofloxacin on MuellereHinton agar ac-
cording to the National Committee for Clinical Laboratory
Standards criteria.12 From 2008, identification to the spe-
cies level were confirmed by 16S rRNA gene sequence
analysis and susceptibility testing was performed using the
E-test method at NTUH.
Data collection and other definitions
This was a cohort review that involved analysis of relevant
clinical, demographic, chest radiographic, and laboratory
data. Data on the presence of underlying diseases, types of
744 H.-K. Wang et al.infection, immunosuppressive therapy, source of Nocardia
isolation, antimicrobial therapy, surgical intervention, and
final outcome were recorded. Patients were considered to
have concomitant bacteremia if non-nocardial species were
present in blood cultures and the patient had symptoms
compatible with bacteremia. Immunosuppressive therapy
was defined as antineoplastic therapy, treatment with
other immunosuppressants (such as azathioprine, cyclo-
sporin, mycophenolate mofetil, tacrolimus, or sirolimus)
within 6 weeks prior to a positive culture for Nocardia, or
corticosteroid therapy. A dose of 20 mg or more of
prednisolone daily for at least 2 weeks or 30 mg of pred-
nisolone for at least 1 week prior to a positive culture for
Nocardia was the definition of corticosteroid therapy.
Sepsis was defined according to the definitions of the
American College of Chest Physicians/Society of Critical
Care Medicine.13
Efficacy of antibiotic treatment was assessed on the
basis of improvement in clinical signs and symptoms and on
in vitro sensitivity to antibiotics. Antibiotic regimens were
also divided into single agent therapies (TMP/SMX, peni-
cillin/cephalosporin, or minocycline) and combined thera-
pies (TMP/SMX, carbapenem, or minocycline in
combination with other antibiotics).
Statistical analysis
The sample size of patients with disseminated nocardiosis
was only 13 in this research, and only three out of 13
disseminated cases showed no lung involved. Because pul-
monary infection and disseminated infection are hard to
differentiate and share more common clinical and micro-
biology features, patients with lung and disseminated
nocardiosis were pooled in the same category to compare
clinical characteristics, outcomes, and antimicrobial results
of the isolates with patients with skin infections. Microsoft
Excel was utilized for all statistical analyses. The pro-
portions were compared using Chi-square test. A p value
<0.05 was considered significant.
Results
According to the laboratory reports and chart recordings,
Nocardia was present in 87 patients, but six of these pa-
tients were defined as colonized based only on the report of
sputum analysis without invasive procedures or new chest
radiological lesions. All six patients had chronic lung dis-
eases and received first generation cephalosporin and cor-
ticosteroids. The remaining 81 patients with culture-proven
invasive nocardiosis were diagnosed at NTUH during the
study period. Clinical manifestations of these 81 patients
included skin involvement only (n Z 44), pulmonary
nocardiosis without dissemination (n Z 24), and dissemi-
nated with or without brain abscess (n Z 13).
A total of 64% of patients (28/44) with skin nocardiosis had
nodular lymphangitis, 30% (13/44) had folliculitis or car-
buncles, 5% (2/44) had pyoderma, and 2% (1/44) had myce-
toma. Half of the patients with cutaneous infections (22/44)
had lesions on their lower extremities, 36% (16/44) had
infection of an upper extremity, and 14% (6/44) patients had
facial infections. Except trauma (2/44), other predisposingfactors for skin nocardiosis were insect bite (3/44), dog bite
(1/44), burns (2/44), and tinea pedis (2/44) with secondary
nocardial wound infection according to chart recording.
A total of 77% of patients (10/13) with multiple organ
involvement had brain abscesses. Of these, seven had both
brain abscess and lung involvement, two had brain abscess
and skin involvement, and one had a localized brain abscess
only. Of the three other multi-system cases, each pre-
sented with lung involvement with nocardial bacteremia,
lymphadenitis, or liver cirrhosis with spontaneous nocardial
peritonitis, independently. Neurological deficits prompted
surgery in 60% of the patients (6/10) with brain abscesses.
Of these six patients, three presented with thalamic, two
with parietal, and one with frontal lobe abscesses. Brain
magnetic resonance imaging (MRI) indicated multiple brain
microabscesses in another four patients, even though these
patients had no neurological signs.
Table 1 shows the basic demographics, clinical features,
and microbiological data for the patients stratified by
infection type. The male-to-female ratio was 1.4:1 and the
mean age was 54.6 years (range, 3e89 years). The most
common underlying disease was chronic lung disease (14%,
11/81); others included diabetes mellitus, malignancy,
autoimmune diseases, transplantation recipients, and ac-
quired immunodeficiency syndrome (AIDS). Chronic lung
disease included bronchiectasis (6/81), bronchial asthma
(4/81), and chronic obstructive pulmonary disease (1/81).
Malignancy included chronic myelocytic leukemia (2/81)
and one each with breast carcinoma, cervical carcinoma,
rectal carcinoma, gingival carcinoma, gastric carcinoma, or
hepatic cell carcinoma. Autoimmune disease included sys-
temic lupus erythematosus (4/81), polymyositis (1/81), and
Paget’s disease (1/81). Transplantation recipients included
renal (3/81), heart (1/81), and bone marrow trans-
plantation (1/81). A total of 40% of patients (32/81)
received immunosuppressive therapy, with 30% (24/81)
having received corticosteroid therapy.
Nocardia were identified to species level using conven-
tional methods and included 46 N. brasiliensis (57%), 32 N.
asteroides (40%), one Nocardia otitidiscaviarum and two
unidentified species. Cutaneous nocardiosis occurred in 54%
of cases (44/81), 91% (40/44) of which were caused by N.
brasiliensis. Only 9% of cutaneous cases (4/44) were caused
by N. asteroides, the species most commonly found in
pulmonary and disseminated nocardiosis. Localized pul-
monary nocardiosis (24/81) was associated with the highest
incidence (63%, 15/24) of concomitant bacteremia or
receiving immunosuppressive treatment (63%, 15/24) and
the highest incidence of steroid use. Among the pulmonary
group, 54% (13/24) had sepsis. A total of 79% of patients
(19/24) were infected by N. asteroides, 13% (3/24) by N.
brasiliensis, 4% (1/24) by N. otitidiscaviarum, and 4% (1/
24) by an unidentified species. Mycobacterium tuberculosis
and Nocardia were recovered together from lung tissues or
sputum in 21% of patients (5/24) in the pulmonary group.
The organisms causing concomitant bacteremia were
Staphylococcus aureus, Salmonella O4 (GrB), Chrys-
eobacterium meningosepticum, Haemophilus para-
influenzae, Streptococcus pneumoniae, Klebsiella
pneumoniae, Proteus mirabilis, Candida albicans, and
Penicillium marneffei. One third of the patients (8/24) in
the pulmonary group died.
Table 1 Demographic and clinical characteristics of patients with skin, lung, and disseminated nocardiosis.x
Variable Total (n Z 81) Skin (n Z 44) Lung (n Z 24) Disseminated
(n Z 13)
Lung þ disseminated
(n Z 37)
p
Age (y, mean  SD) 54.6  20.0 54.5  21.8 53.4  18.7 57.4  17.0 54.8  18.0
Males 47 (58) 24 (55) 16 (67) 7 (54) 23 (62) 0.49
Species of Nocardia
asteroides 32 (40) 4 (9) 19 (79) 9 (69) 28 (76)
brasiliensis 46 (57) 40 (91) 3 (13) 3 (23) 6 (16) <0.01*
otitidiscaviarum 1 (1) 0 (0) 1 (4) 0 (0) 1 (1)
unidentified 2 (2) 0 (0) 1 (4) 1 (8) 2 (5)
Underlying disease
Chronic lung disease 11 (14) 1a (2) 9b (38) 1c (8) 10 (27) <0.05*
Diabetes mellitus 8 (10) 6 (14) 1 (4) 1 (8) 2 (5) 0.22
Malignancy 8 (10) 1d (2) 5e (21) 2f (15) 7 (19) <0.05*
Autoimmune disease 6 (7) 3g (7) 2h (8) 1i (8) 3 (8) 0.83
Transplantation 5 (6) 1j (2) 2k (8) 2l (15) 4 (11) 0.11
AIDS 5 (6) 1 (2) 2 (8) 2 (15) 4 (11) 0.11
Immunosuppressive therapy 32 (40) 11 (25) 15 (63) 6 (46) 21 (57) <0.05*
Corticosteroid usage 24 (30) 8 (18) 11 (46) 5 (38) 16 (43) <0.05*
Concomitant bacteremia 18 (22) 2 (5) 15 (63) 1 (8) 16 (43) <0.05*
Coinfection with TB 8 (9) 2 (5) 5 (21) 1 (8) 6 (16) 0.11
Misdiagnosis as TB 13 (16) 1 (2) 9 (38) 3 (23) 12 (32) <0.05*
Sepsis 16 (36) 1 (2) 13 (54) 2 (15) 15 (41) <0.05*
Antibiotics treatment
Single drug therapy 47 (58) 32 (73) 11 (46) 4 (31) 15 (41) <0.05*
TMP-SMX 33 (41) 21 (48) 9 (38) 3 (23) 12 (32) 0.16
Penicillin or cephalosporin 12 (15) 9 (20) 2 (8) 1 (8) 3 (8) 0.12
Minocycline 2 (2) 2 (5) 0 (0) 0 (0) 0 (0) 0.19
Combined therapy 33 (41) 11 (25) 13 (54) 9 (69) 22 (59) <0.05*
TMP-SMX þ otherm 30 (37) 11 (25) 11 (46) 8 (61) 19 (51) <0.05*
Carbapenem þ othern 2 (2) 0 (0) 2 (8) 0 (0) 2 (5) 0.12
Minocycline þ cephalosporin 1 (1) 0 (0) 0 (0) 1 (8) 0 (0) 0.27
No therapy 1 (1) 1 (2) 0 (0) 0 (0) 0 (0) 0.36
Treatment inadequacy 13 (16) 7 (16) 4 (17) 2 (15) 6 (16) 0.97
Duration of therapy (d)
Mean  SD 78.9  88.8 59.5  51.6 62.5  54.7 175.8  158.6 102.3  115.3
Median 62 56 51 180 76**
Range 3e547 3e195 12e226 7e547 7e547**
Operation 25 (31) 16 (36) 3 (13) 6 (46) 9 (24) 0.24
Overall mortality due
to nocardiasis
11 (14) 0 (0) 8 (33) 3 (23) 11 (30) <0.05*
60 days after diagnosis 9 (11) 0 (0) 7 (29) 2 (15) 9 (24) <0.05*
xComparison of lung and disseminated group with skin group by Chi-square test.
*Statistically significant.
**Because of the large standard deviation and lack of normal distribution, median and range are a better way to show the significance.
AIDS Z acquired immunodeficiency syndrome; CA Z carcinoma; COPD Z chronic obstructive pulmonary disease; SD Z standard de-
viation; SLE Z systemic lupus erythematosus; TB Z Mycobacterium tuberculosis; TMP-SMX Z trimethoprim/sulfamethoxazole.
a Bronchiectasis.
b Asthma (4 patients), bronchiectasis (5 patients).
c COPD.
d SLE (2 patients), polymyositis (1 patient).
e SLE, Paget’s disease.
f SLE.
g Breast CA.
h Cervical CA, rectal CA, gingival CA, chronic myelocytic leukemia (2 patients).
i Gastric CA, hepatic cell CA.
j Renal.
k Heart, bone marrow.
l Renal.
m OtherZ amikacin; penicillin; fluoroquinolone; erythromycin; amikacin þ carbapenem, minocycline, or penicillin; minocycline þ 3rd
generation cephalosporin; or amikacin þ carbapenem þ 3rd generation cephalosporin.
n Penicillin or vancomycin.
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Table 2 Diagnostic methods of cultured-proven nocar-
diosis (81 patients).
No. of patients
Skin pus 46
Lung aspiration 15
Sputum 9
Brain abscess 6a
Pleural effusion 5
Bronchial alveolar lavage 3
Surgical lung tissue 2
Pleural mass 1
Lymph node 1
746 H.-K. Wang et al.In contrast to the pulmonary group, only 8% of patients (1/
13) in the disseminated group had polymicrobial infection. In
the disseminated group, 23% (3/13) of the patients died.
The most common treatment agent, TMP/SMX, was used
as a single (41%, 33/81) agent or in combination therapy
(37%, 30/81). Most cutaneous cases (73%, 32/44) were
treated with a single agent. Combination therapy was more
commonly used in the disseminated cases (69%, 9/13). For
the pulmonary cases, single (46%, 11/24) and combination
therapy (54%, 13/24) were nearly equally common.
In comparison with the skin infection group, patients
with lung and disseminated nocardiosis tended to have N.
asteroides infections and an underlying disease, including
chronic lung disease or malignancy. These patients also
presented with clinically critical conditions, such as sepsis,
and were often initially misdiagnosed as having tubercu-
losis. The patients also tended to receive immunosuppres-
sive treatment and combined antimicrobial therapy, and
they also had increased mortality.
In total, 14% (11/81) of the patients died from nocar-
diosis. The mean survival of the patients who died from
nocardiosis was 42 days (range, 1e161 days), with 55% (6/
11) of these patients having died within 25 days and 82% (9/
11) within 60 days after diagnosis.
Table 2 shows that Nocardia were isolated and cultured
from various sources. The diagnosis of lung nocardiosis
depended on culture of lung aspiration (63%, 15/24),
sputum (38%, 9/24), pleural effusion (21%, 5/24), bron-
choalveolar lavage (13%, 3/24), postpneumonectomy
bronchial tissue (8%, 2/24), or pleural mass (4%, 1/24).
Table 3 shows the radiographic results of the 34 patients
with lung involved nocardiosis (including disseminated type
with lung involvement). Consolidation (71%, 24/34) was the
most common presentation of the radiographic findings,
followed by cavitation (53%, 18/34), nodules or masses
(41%, 14/34), pleural effusion (38%, 13/34), infiltration (9%,
3/34), extension to chest wall (3%, 1/34), and pleura mass
(3%, 1/34). In total, 53% (18/34) of these patients had
bilateral lung involvement.
Table 4 shows the antimicrobial susceptibility of the
Nocardia species from the different infectious sites. The
isolates showed susceptibility to amikacin (97%), TMP/SMX
(94%), gentamicin (80%), minocycline (79%), and cefotax-
ime (79%), but poor susceptibility to ampicillin (17%) and
ciprofloxacin (12%). All of the isolates were resistant to
erythromycin. The Nocardia strains isolated from patients
with disseminated infections (75%, 6/8) tended to have
lower in vitro antimicrobial susceptibility to TMP/SMZ than
those from skin (97%, 34/35) or lung infections (95%, 18/
19). It is worth noting that the isolates from lung infections
had lower susceptibility to cefotaxime (67%, 10/15) than
those from skin infections (86%, 30/35). Based on these
analyses, the isolates from lung and disseminated in-
fections showed significantly lower susceptibility (59%, 16/
27) to gentamicin than those isolated from skin infections
(97%, 34/35).Blood 1
Ascites 1
a Proven by surgical specimens in six patients; another four
patients showed multiple microabscess from brain magnetic
resonance imaging.Discussion
Our results show that the predisposing factors for nocardial
infection include chronic lung disease, diabetes mellitus,malignancy, autoimmune disease, HIV infection, and
transplantation recipients. Although there have been
several published papers describing clinical and microbio-
logic features of nocardiosis in Taiwan, disseminated
nocardiosis is rarely reported.14e16 In this report, we high-
lighted the propensity of central nervous system (CNS)
involvement [77% (10/13)] in disseminated nocardiosis. In
comparison with those with skin infections, patients with
lung and disseminated nocardiosis tended to have chronic
lung disease, malignancy, concomitant bacteremia, were
often misdiagnosed as having tuberculosis, were receiving
immunosuppressive treatments, and demonstrated an
increased mortality. We also note that Nocardia strains
isolated from patients with lung infections or disseminated
infections tend to have lower in vitro antimicrobial sus-
ceptibility than those isolated from skin infections.
Our study population differed from those in previous
studies in that slightly more than half of our patients had
cutaneous nocardiosis andmore than 90% of these cutaneous
cases were caused by N. brasiliensis. Among our patients,
the most common cutaneous presentation was nodular
lymphangitis, which manifested as nodular lesions that pro-
gressed in a sporotrichoid pattern as cellulitis, ulcerative or
bullous lesions, granuloma, and abscesses. In Western
countries, N. asteroids accounts for 60e80% of all cases and
N. brasiliensis is seldom seen. In fact,N. brasiliensis is rarely
found in temperate climates, but it has been recovered from
the soil in many tropical and subtropical countries such as
Taiwan.17e19 N. brasiliensis has been reported to be mostly
associated with cutaneous disease. The patient with myce-
toma on the lower extremity in our cohort had chronic ulcers
for over 10 years. Due to sulfa granules on pathological
findings, the physician had misdiagnosed the lesions as an
Actinomycetes infection. Subsequent identification of
Nocardia allowed this patient to receive the appropriate
management. For proper diagnosis, culture analysis is
necessary. In total, 45% of the cases of skin nocardiosis in this
cohort had no underlying disease. All of the patientswith skin
nocardiosis had survived.
Most of the remainder of our patient population had
pulmonary nocardiosis, either alone (24 cases) or as part of
Table 3 Chest radiographic findings of 34 patients with
lung-involved nocardiosis (both localized lung and dissemi-
nated nocardiosis).
No. of patients (%)
Consolidation 24 (71)
Cavitation 18 (53)
Nodules or masses 14 (41)
Pleural effusion 13 (38)
Infiltration 3 (9)
Extension to chest wall 1 (3)
Pleural mass 1 (3)
Bilateral lung involvement 18 (53)
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nated cases showed no lung involvement. Chronic lung
disease (38%) was the most common underlying disease
among those with isolated pulmonary disease. We cannot
meaningfully compare our results with those of previous
studies because the prevalence of underlying diseases in a
study sample depends greatly on their prevalence in the
populations from which the sample was drawn. For
example, in a report from a large county hospital in Miami,
FL, USA, where there is a high incidence of AIDS, 76% of the
patients with nocardiosis (average age 40 years) had AIDS as
an underlying disease.20 By contrast, in a population
(average age 65 years) from two tertiary hospitals in
Australia, lung disease was the most common underlying
disease (63%) and only 3% of patients had AIDS.21 In a
completely different patient population from the Central
Anatolia region of Turkey, the predominant (44%) underly-
ing medical condition in nocardiosis cases (average age of
31 years) was renal transplantation.22
Inhalation is thought to be responsible for most cases of
invasive pulmonary nocardiosis. The prevalence of respi-
ratory tract colonization may be much higher in patients
with underlying chronic lung disease, such as chronic
bronchitis, emphysema, asthma, or bronchiectasis, andTable 4 Comparison of the antimicrobial susceptibility of Noc
sites.a
Antimicrobial agents Susceptib
Total susceptibility
(%)
Skin (n Z 44) Lun
Amikacin 97 36/36 (100) 16/
TMP/SMZ 94 34/35 (97) 18/
Minocycline 79 30/37 (81) 14/
Cefotaxime 79 30/35 (86) 10/
Gentamicin 80 34/35 (97) 11/
Ampicillin 17 6/36 (17) 3/
Ciprofloxacin 12 3/36 (8) 3/
Erythromycin 0 0/36 (0) 0/
*Statistical significance.
TMP-SMX Z trimethoprim/sulfamethoxazole.
a Comparison by Chi-square test.
b Percentages indicate the percent of cases in which the isolate wa
number of cases in which the isolate was tested against the specificcolonization may be the reason for development of dis-
ease.4 The chest X-rays of patients with lung nocardiosis
had nonspecific findings of consolidation with or without
cavitation, masses or nodules, empyema, or pleural effu-
sion. Patients who are also immunocompromised, invasive
diagnostic procedures such as bronchoalveolar lavage, lung
tissue aspiration, or surgical dissection are essential for
early diagnosis, especially in regards to disseminated
nocardiasis.23
In previous reports, pulmonary tuberculosis coexisting
with nocardiosis is rare, although cases have been reported
in India.24 Five of our pulmonary patients had active pul-
monary tuberculosis in addition to nocardial infection,
presumably because Taiwan has an estimated incidence
rate of pulmonary tuberculosis infection (54.5 new re-
ported tuberculosis/100,000 in 2011).25 Concomitant
infection with Mycobacterium species has been implicated
as a risk factor for development of nocardiosis in HIV-
infected patients.26 Increased reporting of nocardiosis in
Taiwan will be required to determine whether a similar
association exists between nocardial disease and infection
with M. tuberculosis.14
Pulmonary disease and diseases involving depressed im-
mune function (63%) are risk factors for the development of
nocardiosis. Conditions reported to be predictive of
increased mortality from nocardiosis are CNS disease,8,27
severe immunodeficiency,22 and steroid therapy.22,28 In our
patient population, death rates were higher in the pulmo-
nary disease group (33%) than in the disseminated disease
group (23%), and 77% of the patients had CNS involvement.
Most deaths (82%) occurred during the first 2 months after
diagnosis and even they received TMP/SMX (8 patients) or
carbapenem (5 patients) based combination of antimicrobial
therapy. Virtually all patients in these groups had an un-
derlying disease (81%) that presumably increased the risk of
developing nocardiosis. Sepsis was either a direct cause of
death in patients with nocardiosis. Immunosuppressive
therapy increases the risk of concomitant bacteremia by
other microorganisms [S. aureus, Salmonella O4 (GrB), C.
meningosepticum, H. parainfluenzae, S. pneumoniae, K.ardia species isolated from patients with different infection
le no. of cases/test isolates (nb percent sensitive)
g (n Z 24) Disseminated
(n Z 13)
Lung þ disseminated
(n Z 37)
p
17 (94) 6/7 (86) 22/24 (92) 0.08
19 (95) 6/8 (75) 24/27 (89) 0.19
18 (78) 5/7 (71) 19/25 (76) 0.63
15 (67) 6/8 (75) 16/23 (70) 0.14
19 (58) 5/8 (63) 16/27 (59) <0.01*
19 (16) 2/9 (22) 5/28 (18) 0.90
15 (20) 1/9 (11) 4/24 (17) 0.32
18 (0) 0/6 (0) 0/54 (0) d
s sensitive to the antibiotic tested; numbers represent the total
antibiotic.
748 H.-K. Wang et al.pneumoniae, P. mirabilis, C. albicans, and P. marneffei],
which in turn can lead to death or increase the likelihood of
death from nocardiosis.
There is little information on the effect of poor immune
function on the development of nocardiosis. Many patients
with nocardiosis (transplant recipients and HIV positive
patients) are given an anti-nocardial drug (TMP/SMX) for
prophylaxis or treatment of Pneumocystis jiroveci in-
fections commonly present in these populations. TMP/SMX
resistance in patients positive for HIV in this cohort was
25%. The patients positive for HIV that have received TMP/
SMX prophylaxis and are concurrently infected with
Nocardia species will be of substantial interest in future
studies.
In this study, 77% of the patients, were treated with
TMP/SMX, but in some regions, more than half of nocardial
strains are resistant to this drug.29 Although in vitro tests
showed that 93% of our isolates were sensitive to this drug
and that 97% were sensitive to amikacin, the demonstration
of in vitro susceptibility is not always equivalent to clinical
effectiveness.4 In this cohort, Nocardia strains isolated
from patients with lung or disseminated infections tended
to be resistant. TMP/SMX combined with imipenem, or third
generation cephalosporins, or minocycline with or without
amikacin have been the primary regimens for the treatment
of pulmonary, disseminated, or brain nocardiosis or in pa-
tients receiving immunosuppressive agents.3 The mortality
of patients with lung nocardiosis receiving single or com-
bined therapy in this cohort was 33%. The need for com-
bination therapy in patients with lung or disseminated
nocardiosis for empirical therapy prior to antimicrobial
susceptibility has been suggested.
Due to Nocardia tropism towards cerebral tissues, if a
physician is faced with lung or disseminated nocardiosis,
brain MRI should be arranged to rule out brain abscess.1 In
this cohort, four of 10 patients with brain nocardiosis
revealed microabscesses in MRI findings, and these patients
demonstrated no neurological deficit.
The main limitation of this cohort study is its retro-
spective nature. The antimicrobial susceptibility data for
each isolate are not complete and especially the sensitivity
data for carbapenem group, which may be crucial for
treatment of severe infection and central nervous system
infection. Molecular techniques have been used to identify
the species and predict the antimicrobial susceptibility
patterns in previous studies, but molecular typing was not
available for routine identification in every hospital.18
The incidence rate of nocardiosis is considered to be
increasing, due to immunosuppressing agents prescribed to
patients with chronic lung disease, malignancy, or autoim-
mune disease as well as transplantation recipients.14 The
diagnosis depends on a high degree of suspicion. Smears
and culture remain the principal method for diagnosis. If
there is a clinical suspicion of Nocardia infection, physi-
cians should inform the laboratory of the possibility of
Nocardia species, as the laboratory must prolong culture
duration to 3 weeks because some Nocardia species are
slow growing.1
Lung and disseminated nocardiosis can be a significant
cause of morbidity and mortality, especially in patients
with underlying diseases, including chronic lung disease and
malignancy, and patients receiving immunosuppressiveagents. Early recognition of nocardiosis enables a more
rapid initiation of appropriate antimicrobial therapy and a
more favorable outcome. Our results indicate that isolates
from patients with lung or disseminated nocardiosis tend to
be resistant to antimicrobials, which is important when
considering the option of treatment with combined anti-
microbial agents.References
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